TY  - GEN
AU  - Marquez-Megias, Silvia
AU  - Nalda-Molina, Ricardo
AU  - Sanz-Valero, Javier
AU  - Más-Serrano, Patricio
AU  - Diaz-Gonzalez, Marcos
AU  - Candela-Boix, Maria Remedios
AU  - Ramon-Lopez, Amelia
PY  - 2022
DO  - 10.3390/pharmaceutics14051009
SN  - 1999-4923
UR  - http://hdl.handle.net/20.500.12105/15183
AB  - Infliximab and adalimumab are monoclonal antibodies against tumor necrosis factor (anti-TNF) used to manage inflammatory bowel disease (IBD). Therapeutic Drug Monitoring (TDM) has been proven to prevent immunogenicity, to achieve better long-term...
LA  - eng
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
KW  - Inflammatory bowel diseases
KW  - Drug monitoring
KW  - Pharmacokinetics
KW  - Tumor necrosis factor inhibitors
KW  - Adalimumab
KW  - Infliximab
KW  - Cost–benefit analysis
KW  - Cost-effectiveness
TI  - Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
TY  - review article
ER  -